Effect of vaccination status on CORADS and computed tomography severity score in hospitalized COVID-19 patients: A retrospective study

Table 1 Computed tomography severity scoring

CT severity score	Extent of lesions for each lung lobe, %
0	0
1	< 5
2	5-25
3	26-50
4	51-75
5	> 75

CT: Computed tomography.

Table 2 Evaluations of the groups by age and gender

	n	Age	Gender
		mean ± SD	Male	Female
1Unvaccinated	63	50.95 ± 13.54	27 (42.9)	36 (57.1)
2Single dose CoronaVac	20	60.75 ± 8.82	9 (45.0)	11 (55.0)
3Single dose BioNTech	24	50.1 ± 11.015	7 (29.2)	17 (70.8)
4Two doses CoronaVac	38	73.55 ± 9.34	21 (55.3)	17 (44.4)
5Two doses BioNTech	40	59.13 ± 13.88	24 (60)	16 (40)
6Three doses	39	74.23 ± 10.29	19 (48.7)	20 (51.3)
Total	224	61.09 ± 15.36	107 (47.8)	117 (52.0)
P value		0.001a,c	0.204b
Post hoc		1 < 2, 4, 5, 6; 2 > 3; 2 < 4, 6; 3 < 4, 6; 4 > 5; 5 < 6	-

^aOneway Anova test.

^bPearson chi-square test.

^cP < 0.01.

Table 3 Evaluation of computed tomography severity scores of the groups

Group	n	CT severity scores				P value
		Mean	SD	Median	Min-Max
1Unvaccinated	63	14.17	4.56	15	5-23	0.002b
2Single dose CoronaVac	20	13.35	4.12	13.5	5-21
3Single dose BioNTech	24	11.58	5.29	11.5	5-20	1 > 4; P = 0.015a
4Two doses CoronaVac	38	10.87	4.42	10.5	5-19	1 > 5; P = 0.021a
5Two doses BioNTech	40	11.28	5.25	12.0	5-21	1 > 6; P = 0.045a
6Three doses	39	10.85	5.01	9	5-22
Total	224	12.17	4.950	12	5-23

Kruskal Wallis test & post hoc Dunn test.

^aP < 0.05.

^bP < 0.01. CT: Computed tomography.

Table 4 Evaluation of groups according to CORADS classification

Group	n	CORADS		P value
		Typical	Not typical
1Unvaccinated	63	57 (90.5)	6 (9.5)	0.001a
2Single dose CoronaVac	20	18 (90)	2 (10.3)
3Single dose BioNTech	24	14 (58.3)	10 (41.7)
4Two doses CoronaVac	38	26 (68.4)	12 (31.6)
5Two doses BioNTech	40	15 (37.5)	25 (62.5)
6Three doses	39	17 (43.6)	22 (56.4)
Total	224	147 (65.6)	77 (34.4)

^aP < 0.01. Pearson chi-square test.

Table 5 Distribution of Acute Phase Variables by Groups

		1Unvaccinated	2Single dose CoronoVac	3Single dose BioNTech	4Two doses CoronaVac	5Two doses BioNTech	6Three doses	P valuec	Post Hoc
CRP	mean ± SD	52.95 ± 40.49	49.75 ± 31.26	34.0 ± 32.3	66.58 ± 52.75	84.35 ± 72.99	81 ± 62.88	0.006a	3 < 4, 5, 6
	Median (Min-Max)	46 (3-173)	39.5 (12-124)	22 (2-106)	59 (4-204)	66 (2-341)	54 (2-286)
LDH	mean ± SD	359.17 ± 164.41	315.2 ± 58.2	331.83 ± 116.61	401.5 ± 305.74	294.05 ± 89.57	276.36 ± 94.2	0.001a	6 < 5, 3, 1; 5 < 1
	Median (Min-Max)	359 (164-1213)	311 (195-461)	328 (207-692)	368 (156-1943)	290 (152-640)	273 (131-538)
Lymphocyte count	mean ± SD	1335.4 ± 512.04	1396.5 ± 470.93	1502.92 ± 724.42	1637.11 ± 1896.86	1628.75 ± 86.02	1477.95 ± 867.82	0.660
	Median (Min-Max)	1290 (390-2790)	1375 (510-2050)	1340 (420-3450)	1200 (340-12360)	1575 (550-5200)	1320 (260-4640)
Procalcitonin	mean ± SD	0.52 ± 0.94	0.28 ± 0.29	0.13 ± 0.13	0.77 ± 2.39	0.25 ± 0.2	0.27 ± 0.31	0.001a	3 < 1, 2, 4, 5
	Median (Min-Max)	0.3 (0.1-6)	0.3 (0.1-1.3)	0.1 (0.1-0.7)	0.2 (0.1-15)	0.1 (0.1-0.7)	0.1 (0.1-1.2)
D-DIMER	mean ± SD	1041.08 ± 1559.79	955.95 ± 1156.16	1396.71 ± 1608.97	1561.63 ± 2118.83	1462.2 ± 2934.47	1388.41 ± 1922.45	0.106
	Median (Min-Max)	596 (24-11805)	549.5 (133-4661)	714.5 (140-6193)	942.5 (251-13077)	622 (166-17459)	820 (194-9440)

^aP < 0.01.

^cKruskal Wallis test & post hoc Dunn test.